Klaus Ley - Translating An Atherosclerosis Vaccine To Clinical Trials

Klaus Ley - Translating an Atherosclerosis Vaccine to Clinical Trials

Human Immunome Project

Scientist Stories: Klaus Ley, Translating an Atherosclerosis Vaccine to Clinical Trials

Klaus Ley, Distinguished Lecturer ATVB|PVD 2017

Cardiovascular Research Discoveries - February 2021 (Klaus Ley and Clément Cochain)

Cardiovascular Research

Life Without Disease | A vaccine tp prevent heart attacks? || teaser

La Jolla Institute for Immunology

Klaus Ley, Ph.D. on San Diego 6 XETV

La Jolla Institute for Immunology

Understanding vaccines with Klaus Ley

Medical College of Georgia

Klaus Ley, M.D.

DM Clinical Research's Dr. Holloway Discusses Novavax Teen COVID-19 Vaccine Clinical Trial

DM Clinical Research

Advances in RSV vaccine development: translating experimental findings to clinical trials

COVID-19 | Get the Facts: Minority Participation in Vaccination Clinical Trials

Do we have evidence for the ‘inflammatory hypothesis’ in atherosclerosis?

Vaccines | Rochelle - Clinical Trial Participant

Department of Health and Social Care

What is a Phase 3 Clinical Trial for a Vaccine Candidate?

National Institutes of Health (NIH)

How clinical trials look like and why do we need them?

Novavax COVID-19 Vaccine May Be Highly Effective, Clinical Trials Show

Vaccines | What you need to know about clinical trials

Department of Health and Social Care

Atherosclerosis in Mice

JoVE (Journal of Visualized Experiments)

Pfizer, BioNTech to start clinical trials for omicron vaccine

Sponsored webinar | How Atherosclerosis Guides Diagnosis, Prognosis, and Clinical Decision Making

Society of Cardiovascular Computed Tomography